CD274 and hepatocellular carcinoma: Several other ICIs, including PD-1 (Camrelizumab and Sintilimab), PD-L1 (Durvalumab), CTLA-4 (Tremelimumab) and VEGF (Bevacizumab) antibodies, are being investigated as mono- or combination therapy in ongoing phase III trials in patients with advanced HCC.